Company Overview
Anjarium Biosciences AG is a leading biotech entity headquartered in Schlieren, Zurich, Switzerland, established in 2016. The company is at the forefront of innovation in cell and gene therapy, specializing in the development of non-viral gene therapies. These therapies are aimed at reducing immunogenicity and improving delivery across diverse applications.
Core Offerings and Technology
Anjarium's hallmark is its synthetic DNA technology, an enzymatic, cell-free platform that offers customizable, stable synthetic DNA constructs at scale. Key applications of this technology include Adeno-associated Virus (AAV), mRNA, and Lentivirus, which are instrumental in advancing genetic medicines.
- Increased purity: Eliminates unwanted bacterial sequences, ensuring cleaner outputs.
- Scalability: From microgram to multigram batches.
- Rapid production: Faster timelines compared to conventional plasmid systems.
- Structural stability and flexibility: Integrates hairpin-ended structures to protect DNA integrity and support complex transgene sequences.
Recent Achievements
In October 2021, Anjarium successfully concluded a Series A funding round, securing USD 60.4 million. This funding is propelling the development of the company's next-generation gene therapies. Furthermore, the DNA platform's effectiveness was prominently featured at the ASGCT meetings, showcasing its application advances in cell and gene therapies.
Leadership
The executive team comprises:
- Stephen Yoo, MD: Chief Executive Officer, with over 14 years of experience in biotech and life sciences, and academic credentials from the University of California, Berkeley, and the David Geffen School of Medicine at UCLA.
- Otmane Boussif, DSc: Chief Technology Officer, bringing more than 25 years of experience, including pivotal roles in biopharmaceuticals like Novartis, now leading advancements in gene therapy technologies at Anjarium.
- Nate Massari: Chief Business Officer, with 25+ years in strategy, product development, marketing, and sales leadership, previously involved in corporate development and strategy at Aytu BioPharma.
Strategic Focus and Partnerships
Anjarium pioneers advancements in genetic medicine through strategic alliances with leading investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital (a Citadel company). The leadership team's extensive expertise facilitates the progression of innovative DNA and vector production technologies from discovery to clinical and commercial stages.
Contact Information
- Location: Wagistrasse 23, Schlieren, Zurich, CH-8952, Switzerland
- Phone: +41 44 552 3888
- Website: [www.anjarium.com](http://www.anjarium.com/)
Competitor Profiling for Anjarium Biosciences AG
Competitors
Anjarium operates amidst formidable competitors:
- New Amsterdam Pharma: Focuses on cardiovascular disease and lipid-related conditions, with notable financial activities and a presence on Nasdaq.
- LoQus23 Therapeutics: Targets neurodegeneration through therapies addressing aberrant mismatch repair.
- Constructive Bio: Excels in synthetic biology, specializing in whole-genome writing and engineered translation.
- Codiak Biosciences: Develops exosome-based therapeutics, especially for cancer.
- Lonza Group AG: Offers extensive contract manufacturing for biopharmaceutical sectors and holds a significant global presence.
Investment and Funding
Anjarium's significant financial backing comes from investors like Surveyor Capital, Pfizer Venture Investments, Gimv, Abingworth, and Omega Funds, affirming the company’s pioneering role in non-viral gene therapy landscapes.
Strategic Initiatives
With CHF 55.5 million (approximately $61 million) raised in Series A funding, Anjarium is set to expand its next-generation non-viral gene therapies. Such financial strength fortifies its foundation for ongoing growth and innovation.
Key Market Position
Recognized within the exosome market sector, Anjarium is considered a key player, driving forward advanced applications where demand continues to rise.
Note: Anjarium Biosciences' robust leadership, strategic partnerships, and proactive market positioning underscore its potential in the realms of genetic medicine and biotechnological innovation, with continuous observation necessary in this rapidly evolving sector.
